Last reviewed · How we verify
LMWH (Fragmin, dalteparin)
Dalteparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factor Xa and thrombin.
Dalteparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factor Xa and thrombin. Used for Venous thromboembolism prophylaxis in surgical patients, Treatment of acute deep vein thrombosis, Treatment of acute pulmonary embolism.
At a glance
| Generic name | LMWH (Fragmin, dalteparin) |
|---|---|
| Also known as | Fragmin |
| Sponsor | McMaster University |
| Drug class | Low-molecular-weight heparin (LMWH) |
| Target | Factor Xa, Thrombin (Factor IIa), Antithrombin III |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Dalteparin binds to and potentiates antithrombin III, a natural anticoagulant, leading to inactivation of activated factor X (Xa) and thrombin (factor IIa). This prevents the formation and extension of fibrin clots. LMWH agents have more predictable pharmacokinetics and longer half-lives compared to unfractionated heparin, allowing for subcutaneous dosing.
Approved indications
- Venous thromboembolism prophylaxis in surgical patients
- Treatment of acute deep vein thrombosis
- Treatment of acute pulmonary embolism
- Unstable angina and non-ST elevation myocardial infarction
Common side effects
- Bleeding
- Thrombocytopenia
- Injection site hematoma
- Elevated transaminases
Key clinical trials
- Effect of Anticoagulant Therapy on Endometrial Receptivity and Pregnancy Outcomes in Infertility
- Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism (PHASE4)
- Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma
- Timing of Venous Thromboembolism Prophylaxis in Patients With Hypertensive Intracerebral Hemorrhage (NA)
- Efficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LS (NA)
- Dose-adjustment of Enoxaparin by a Bayesian Pharmacological Approach in Pediatric Kidney Transplant Recipients (OPTI-TREX) (PHASE4)
- Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia (PHASE4)
- The Intensive Care Platform Trial (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LMWH (Fragmin, dalteparin) CI brief — competitive landscape report
- LMWH (Fragmin, dalteparin) updates RSS · CI watch RSS
- McMaster University portfolio CI